Source: BioRxiv

The pandemic coronavirus COVID-19 affected global health from the end of 2019 to 2020 and may challenge global health in the future. There have been reports of Chloroquine (CQ) and Hydroxychloroquine (HCQ) used in clinical treatment.

In our study, we used CCK-8 stain, flow cytometry and immunofluorescent stain to evaluated the toxicity and autophagy of CQ and HCQ respectively on ACE2 high expressed HEK293T cells (ACE2hi cells). We further analysied the binding character of CQ and HCQ to ACE2 by molecular docking, surface plasmon resonance (SPR) assays and molecule docking, COVID-19 spike pseudotype virus was also taken to investigate the suppression viropexis effect of CQ and HCQ.

Results showed that HCQ is slightly more toxic to ACE2hi cells than CQ, both CQ and HCQ could bind to ACE2, and they also exhibit equivalent suppression effect for the entrance of COVID-19 Spike pseudotype virus into ACE2hi cells.

Our finding provides a theoretical and experimental basis for the clinical treatment of CQ and HCQ for COVID-19.

Nan Wang, Shengli Han, Rui Liu, Liesu Meng, Huaizhen He, Yongjing Zhang, Cheng Wang, Yanni Lv, Jue Wang, Xiaowei Li, Yuanyuan Ding, Jia Fu, Yajing Hou, Wen Lu, Weina Ma, Yingzhuan Zhan, Bingling Dai, Jie Zhang, Xiaoyan Pan, Shiling Hu, Jiapan Gao, Qianqian Jia, Liyang Zhang, Shuai Ge, Saisai Wang, Peida Liang, Tian Hu, Jiayu Lu, Xiangjun Wang, Huaxin Zhou, Wenjing Ta, Yuejin Wang, Shemin Lu, Langchong He

A new study shows hydroxychloroquine would get out of hospital faster

Hydroxychloroquine is currently being used with great success – Qatar has a case fatality rate of only 0.04% with 21 deaths out of 43,714 cases.

Honduras: Catracho, the Covid-19 treatment method the country is using to reduce deaths within an impoverished health system

Firefighter, paramedic and now corona virus survivor Joe Biasi treated with hydroxychloroquine

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »